Table 1 Inclusion criteria based on the PICOS format for the study conducted
PICOS | Inclusion Criteria | Exclusion Criteria |
|---|---|---|
Participants | ● Pediatrics including neonateswith microscopically confirmed, uncomplicated P. falciparum orVivax malaria. ● With mono-infections | ● In-vitro studies ● Adults, ● All with sever malaria ● All with other types of malaria and co-infections/mixed infections |
Interventions | ● Treatment at least three-day course of an ACT (fixed dosed, co-blistered, or individually packaged (loose)) | ● Prophylaxis ● Studies that do not report ACT ● For non-comparative trials, those with ACT and other drugs with antimalarial properties ● Artemisinin mono-therapy |
Comparison | An ACT with or without comparative arm interventions (ACT with ACT, ACT with non-ACT, ACT alone) | ● Studies that do not report an ACT |
Outcome measures | ● Efficacy: PCR corrected day 28 and 42 ACPR and ● Safety: Adverse drug events including associated deaths | ● Follow-ups less than day 28 ● Retreatments |
Studies | ● All study designs globally ● Published in English ● No restriction to number of authors ● Published until March 06, 2020 ● phase III/IV clinical trials | ● News, communication, qualitative studies, case reports ● all non-published studies and published in non –English languages ● Phase I/II trials. |
Overall | ● Must fulfill all above inclusion criteria’s | ● Must not include either of the above |